Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camicinal for L-DOPA PK in Parkinson's Disease
NCT01602549Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing GSK962040 with Placebo (2 arms). Primary endpoints: Dose-normalized Levodopa Area Under the Plasma Concentration-time Curve From Zero to 4 Hours, Dose-normalized Levodopa Maximum Observed Concentration at Day 8 and 2 more. Started Jul 2012; status: completed.
02
Drugs
camicinal
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01602549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602549.